Generated by All in One SEO v4.9.1.1, this is an llms.txt file, used by LLMs to index the site. # Lophora ## Sitemaps - [XML Sitemap](https://www.lophora.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Lophora Announces First Subjects Dosed in Phase 1 Clinical Trial of LPH-5](https://www.lophora.com/lophora-announces-first-subjects-dosed-in-phase-1-clinical-trial-of-lph-5/) - Lophora ApS, a Danish biotech company focused on next-generation psychedelic therapies for central nervous system disorders, today announced that the first subjects have been successfully dosed in the Phase 1 clinical trial of its lead candidate, LPH-5, a novel serotonergic compound. The ongoing study is being conducted in healthy volunteers at Biotrial in Rennes, - [Lophora Raises $3 million and Recieves Approval from EMA to Initiate Phase I Clinical Trial for LPH-5](https://www.lophora.com/medwatch/) - Lophora featured in Medwatch (in Danish) Read the article - [Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5](https://www.lophora.com/lophora-successfully-completes-3m-financing-to-propel-phase-i-trials-for-lead-cns-drug-lph-5/) - After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has successfully completed an over $3 million capital raise to support this next phase and further bolster the company’s robust patent portfolio. The financing round, which garnered strong interest from both new and existing investors, underscores - [Lophora enters Research Collaboration with Beckley Psytech](https://www.lophora.com/lophora-enters-research-collaboration-with-beckley-psytech/) - Lophora and Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced the companies have entered into a research and development collaboration. Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on - [Lophora collaborates with Beckley Psytech](https://www.lophora.com/lophora-collaborates-with-beckley-psytech/) - Lophora has entered into a research and development collaboration with Beckley Psytech Limited. Read the article - [Companies attract venture funding for redesigned psychedelic drugs](https://www.lophora.com/companies-attract-venture-funding-for-redesigned-psychedelic-drugs/) - CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 in the landscape of next generation psychedelics. Read the article - [Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.](https://www.lophora.com/lophora-receives-approval-from-ema-to-initiate-phase-i-clinical-trial-for-lph-5-a-promising-treatment-for-depression/) - Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase I, first-in-man, randomized, placebo-controlled, single-dose escalation study for LPH-5. This study will investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of - [Next-generation psychedelics: should new agents skip the trip?](https://www.lophora.com/next-generation-psychedelics-should-new-agents-skip-the-trip/) - CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next generation psychedelics. https://www.nature.com/articles/s41587-024-02285-1 nature.com, CSO Jesper L. Kristensen, LPH-5 in, next generation psychedelics. - [Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression](https://www.lophora.com/lophora-initiates-preclinical-development-of-lph-5-for-treatment-resistant-depression/) - Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance their first-in-class lead candidate LPH-5. In early 2020, Lophora was successfully accepted into the Creation House program at BioInnovation Institute and granted a $1.5M convertible loan by the Novo Nordisk Foundation. Lophora will now advance their lead candidate LPH-5 through pre-clinical development in order to de-risk the compound prior to the initiation of first-in-human studies towards the end of 2021. Amongst other things, this involves the large-scale production of LPH-5, followed by a detailed characterization of the molecule’s safety profile, which is a key regulatory requirement prior to initiating clinical studies. - [Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression](https://www.lophora.com/lophora-receives-additional-funding-to-complete-pre-clinical-development-of-lph-5-a-novel-and-innovative-agent-to-address-treatment-resistant-depression/) - Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional support of US$1.6M from The Danish Growth Fund (Vækstfonden) and the Danish Innovation Fund (Innovationsfonden), allowing Lop hora to complete pre-clinical development of its first-in-class lead candidate LPH-5, which is expected to enter Phase I studies in early 2022. - [Lophora completes preclinical development of LPH-5 for treatment-resistant depression](https://www.lophora.com/lophora-completes-preclinical-development-of-lph-5-for-treatment-resistant-depression/) - Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant Depression. No toxicology or histopathology findings. - [Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I](https://www.lophora.com/lophora-closes-bridge-round-to-strengthen-global-patent-portfolio-and-prepare-for-phase-i/) - Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support of ~US$1M from a syndicate of family offices and experienced biotech investors. The new investment allows Lophora to strengthen its global composition of matter patent portfolio and produce GMP-grade drug product of its first-in-class lead candidate LPH-5, which is ready to enter Phase I studies. - [Structure-Activity Relationships of Lophora’s selective serotonin 5-HT2A receptor agonists published in the Journal of Medicinal Chemistry](https://www.lophora.com/structure-activity-relationships-of-lophoras-selective-serotonin-5-ht2a-receptor-agonists-published-in-the-journal-of-medicinal-chemistry/) - The Lophora team has published a paper detailing the discovery and structure of the lead clinical candidate LPH-5 in the Journal of Medicinal Chemistry. The Lophora team is pleased to announce the publication detailing the discovery and structure of our lead clinical candidate LPH-5 in this month’s Journal of Medicinal Chemistry. LPH-5 is a - [Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.](https://www.lophora.com/lophora-submits-clinical-trial-authorisation-cta-application-to-the-french-medicines-agency-ansm-for-lead-cns-drug-lph-5/) - Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders, announced today that it has submitted a Clinical Trial Application (CTA) for its lead drug program LPH-5. The CTA is directed towards a Phase I first-in-human study to assess the safety, tolerability, pharmacokinetics and potential ## Pages - [Home](https://www.lophora.com/) - Lophora, founded in 2018, develops next-gen psychedelic medicines for mental illness, advancing LPH-5 with BioInnovation funding. Read more about us. - [Contact](https://www.lophora.com/contact/) - Contact us: Visit us, e-mail us, call us or stay updated - [Leadership](https://www.lophora.com/leadership/) - Leadership Executive Management Bo Tandrup MSc.(pharm.) CEO/Co-Founder Mr. Tandrup is a distinguished pharmaceutical executive and serial entrepreneur with +15 years of experience managing early-stage life science companies. He began his pharmaceutical career at Sanofi-Aventis in 1998 and in 2006 he founded his first company, Alkalon, a successful VC-backed global nicotine business, that was the first - [Patents](https://www.lophora.com/patents/) - Patents Lophoras IP portfolio includes a composition of matter patent covering a wide area of chemical space encompassing millions of novel compounds within a novel compound class of phenethylamine derived psychedelics- granted in the US, Europe and elsewhere. Furthermore, Lophora controls the rights to the proprietary manufacture of lead candidate LPH-5 and fast follower LPH-48, - [Home](https://www.lophora.com/home-2/) - Developing Next Generation Neuroactive Medicines to Treat Mental Illness Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, neuroactive medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders. Join Newsletter About us The company has identified and patented a new class of - [Pipeline](https://www.lophora.com/pipeline/) - Pipeline Lophora’s rich and easily expandable pipeline can address multiple psychiatric disorders. Like other agonists of the 5-HT2A receptor, LPH-5 is believed to be a potent psychoplastogen and has shown anti-depressant effect in an animal model of depression at doses that do not induce hallucinogenic effects, indicating that this compound could be used for - [Scientific Publications](https://www.lophora.com/scientific-publications/) - Scientific Publications Anders Asbjørn Jensen and Emil Märcher-Rørsted in the laboratories in Copenhagen (October 2020). Lophora’s founders have a proven track record of academic excellence demonstrated by numerous influential scientific publications within the field of psychedelic research published in peer reviewed journals over the past 15 years. Representative scientific publications from the Lophora-research team: Discovery - [LPH-5 (Phase 1)](https://www.lophora.com/lph-5/) - LPH-5 LPH-5 is a novel phenethylamine-derived therapeutic candidate with high selectivity for the Serotonin 2A receptor and excellent drug-like properties LPH-5 shows not only selectivity for the serotonine 2A receptor over an extensive range of other pharmacological targets but has very low activity at the off-target homolog: the Serotonin 2B receptor, which is implicated in - [LPH-48 (pre-clinical)](https://www.lophora.com/lph-48/) - LPH-48 LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. Designed as a fast-follower to LPH-5, LPH-48shows significantly faster metabolism, indicating a much shorter activity profile in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and - [FAQ](https://www.lophora.com/faq/) - Explore Lophora's cutting-edge psychedelic medicines: LPH-5 and LPH-48. Learn about our unique properties, therapeutic potential, and safety considerations. - [News](https://www.lophora.com/news/) - News Join Newsletter Latest Updates from Lophora Lophora Successfully Completes $3M Financing to Propel Phase I Trials After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical… Read More January 15, 2025 Lophora Receives Approval from EMA to Initiate Phase I Clinical Lophora, a clinical-stage CNS drug discovery company developing - [Investors](https://www.lophora.com/investors/) - Explore Lophora's funding partners and recent transition from stealth mode at JPM 2024. Learn about our plans for investors. - [About us](https://www.lophora.com/about-us/) - About Us Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders. Lophora Founders Team at BioInnovation Institute (October 2020). From left: Emil Märcher-Rørsted, Jesper Langgaard Kristensen, Bo Tandrup, Anders Asbjørn Jensen. The - [Alliances and Partners](https://www.lophora.com/alliances-and-partners/) - Alliances and Partners Lophora’s R&D work is conducted in collaboration with a range of academic and industrial partners: University of Copenhagen, University of Aarhus, Louisiana State University, WuXi AppTec, STA, Eurofins, Sygnature, Biotrial, Ardena and LIOS Previous Next - [Drug Design](https://www.lophora.com/drug-design/) - Drug design Embracing the future of psychedelic medicine, rational drug-design, building on decades of scientific research into psychedelic drug scaffolds, has led the Lophora R&D team to the discovery of a novel compound class in which the problematic off-target effects of classic psychedelics have been systematically engineered out. Having spent the past decades developing selective - [test](https://www.lophora.com/test/) - News More news - [Corporate Directory](https://www.lophora.com/leadership/corporate-directory/) - Corporate directory Lophora ApS Gyldenlundsvej 21, 12920 CharlottenlundGreater Copenhagen AreaDenmark Phone: +45 51 86 84 82Registered office: CharlottenlundCVR no.: 39 87 10 33Financial year: 01.01 – 31.12 Auditor Beierholm AccountantsCVR no. 32 89 54 68Thomas Thomsen, State Authorized Public AccountantMNE-no. mne34079 Lawyer DLA PiperCVR no. 35 20 93 52Martin Lavesen, Country Managing Partner ## My Templates - [Leadership](https://www.lophora.com/?elementor_library=leadership) - Team & Board Lophora is led by an experienced executive team with a strong scientific and commercial track record. Meet the founders, board members, scientific advisors and key team behind the programs. Executive Management Board of Directors Team Members & Advisors Executive Management Bo Tandrup, MSc (pharm.) — CEO / Co-Founder Mr. Tandrup is a - [Global footer](https://www.lophora.com/?elementor_library=global-footer) - Lophora is developing novel, next-generation, neuroactive medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders. Quick Links Registered Office Gyldenlundsvej 21, 1.2920 CharlottenlundGreater Copenhagen AreaDenmark Company/VAT number: DK39871033 Email: contact@lophora.com Phone: +45 51 86 84 82 - [Elementor Loop Item #1041](https://www.lophora.com/?elementor_library=elementor-loop-item-2) - [Elementor Loop Item #3139](https://www.lophora.com/?elementor_library=elementor-loop-item-3) - [Elementor Loop Item #3142](https://www.lophora.com/?elementor_library=elementor-loop-item-4) - [Elementor Loop Item #1041 - Copy](https://www.lophora.com/?elementor_library=elementor-loop-item-1041-copy) - [Changing background menu](https://www.lophora.com/?elementor_library=changing-background-menu) - [Default Kit](https://www.lophora.com/?elementor_library=default-kit) - [News post template](https://www.lophora.com/?elementor_library=news-post-template) - Back to news - [Pipeline wireframe fallback](https://www.lophora.com/?elementor_library=pipeline-wireframe-fallback) - Pipeline Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Family Lorem ipsum dolor sit Lorem ipsum dolor sit Lorem ipsum dolor sit Lorem ipsum dolor sit Family 1 – Lorem ipsum dolor sit amet, Family 2 – Lorem ipsum dolor sit amet, Family 3 – - [News fp](https://www.lophora.com/?elementor_library=news-fp) - [Elementor Loop Item #623](https://www.lophora.com/?elementor_library=elementor-loop-item) - [News archive](https://www.lophora.com/?elementor_library=news-archive) - News News Placeholder 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor… Read More October 9, 2023 News Placeholder 3 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor… Read More October 9, 2023 News placeholder 2 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod ## Categories - [Uncategorized](https://www.lophora.com/category/uncategorized/) ## Tags - [Media](https://www.lophora.com/tag/media/) - [News](https://www.lophora.com/tag/news/)